Advances in Systemic Treatment of Breast Cancer.

Targeted therapies, antibody-drug conjugates, and immunotherapy have significantly advanced breast cancer treatment since 2020, improving outcomes across subtypes.

• Why it matters: These developments address the need for more personalized, effective treatments tailored to tumor biology, but challenges remain in optimizing sequencing and ensuring equitable access.
• What they did: The study reviews recent progress, including biomarker-guided strategies, new drug approvals like trastuzumab deruxtecan, and immune checkpoint inhibitors, based on extensive clinical data.
• The result: These innovations enable risk-adapted treatment approaches, improving survival and quality of life, while highlighting ongoing efforts to refine therapy sequencing and biomarker identification.